Leave a little sharper than you arrived.

DNA immunotherapy VGX-3100 shows promise as a nonsurgical option for precancerous cervical lesions

A DNA immunotherapy could spare women from surgery for precancerous cervical lesions. In a phase 3 trial, VGX-3100 achieved histologic regression and HPV-16/18 clearance in 52.5% of patients vs. 35.3% on placebo — a meaningful difference with a strong safety profile. Researchers say it could become a viable nonsurgical alternative for managing HPV-driven cervical disease.